With Swiss pickup, Pfizer adds CMV candidate to growing vaccines unit

After 2014's growth spurt, Pfizer's ($PFE) vaccines unit hasn't finished expanding. The pharma giant grabbed privately held Swiss company Redvax for an undisclosed sum, adding a preclinical human cytomegalovirus (CMV) vaccine candidate, and a tech platform and IP related to a second, undisclosed vaccine program. But Pfizer will need to keep bulking up if it wants to stay competitive with its Big Pharma peers. It currently trails Merck ($MRK), Sanofi ($SNY) and GlaxoSmithKline ($GSK) in the global vaccines market, and with Glaxo's deal for Novartis' ($NVS) vaccines unit, that top 3 will only be getting more difficult to crack. More